+

WO2018200813A1 - Compositions et procédés de détection de signatures microbiennes associées à différents types de cancer du sein - Google Patents

Compositions et procédés de détection de signatures microbiennes associées à différents types de cancer du sein Download PDF

Info

Publication number
WO2018200813A1
WO2018200813A1 PCT/US2018/029572 US2018029572W WO2018200813A1 WO 2018200813 A1 WO2018200813 A1 WO 2018200813A1 US 2018029572 W US2018029572 W US 2018029572W WO 2018200813 A1 WO2018200813 A1 WO 2018200813A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
hybridization
tumor tissue
detectably
pathochip
Prior art date
Application number
PCT/US2018/029572
Other languages
English (en)
Inventor
Erle S. Robertson
James C. ALWINE
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Publication of WO2018200813A1 publication Critical patent/WO2018200813A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • breast cancer the second leading cause of cancer death in women, is responsible for the death of 1 in 36 women.
  • endocrine receptor (estrogen or progesterone receptor) positive BRER
  • HER2 human epidermal growth factor receptor 2
  • BRTP triple positive (estrogen, progesterone and HER2 receptor positive)
  • BRTN triple negative (absence of estrogen, progesterone and HER2 receptors)
  • the hormone receptor positive breast cancers (BRER, BRTP) respond to endocrine therapy and show better prognosis
  • the hormone receptor negative types (BRHR, BRTN) are more aggressive, non-responsive to endocrine therapy and have poor prognosis.
  • BRTN cancer is seen in 15-20% of breast cancer patients, is the most aggressive of all the breast cancers, is unresponsive to treatment, highly angiogenic, proliferative and has the lowest survival rate.
  • cancer-type specific microbiome signatures may provide biomarkers for early diagnosis, prognosis and treatment strategies.
  • the PathoChip is a pan-pathogen array containing oligonucleotide probes for the detection of all known, sequenced viruses, as well as known human bacterial, parasitic and fungal pathogens (Baldwin et al. MBio. 2014; 5 : e01714-14). Additionally, PathoChip contains viral family specific conserved probes that allow for detection of uncharacterized members of the viral families.
  • the PathoChip screen includes a whole genome and transcriptome amplification step that allows detection of very low copy number of both DNA and RNA viruses and micro-organisms from cancer tissues.
  • the present invention satisfies this need.
  • the present invention relates to compositions and methods for detecting, treating, and distinguishing between different types of breast cancer.
  • One aspect of the invention includes a method of detecting breast cancer in a tumor tissue sample from a subject.
  • the method comprises hybridizing a detectably- labeled nucleic acid from the tumor tissue sample to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably-labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern.
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared. When the first hybridization pattern is substantially a microbial hybridization signature and the second hybridization pattern is substantially not a microbial hybridization signature, breast cancer is detected in the tumor tissue sample.
  • Another aspect of the invention includes a method of detecting breast cancer in a tumor tissue sample from a subject.
  • the method comprises hybridizing a detectably- labeled nucleic acid from the tumor tissue sample to a first microarray comprising at least three nucleic acid probes from microbes selected from the group consisting of
  • Adenoviridae Anelloviridae, Arenaviridae, Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Herpesviridae, Iridoviridae, Papillomaviridae, Paramyxoviridae,
  • Parvoviridae Picornaviridae, Poxviridae, Reoviridae, Retroviridae and Rhabdoviridae, Actinomyces, Bartonella, Brevundimonas, Coxiella, Mobiluncus, Mycobacterium, Rickettsia and Sphingomonas to generate a first hybridization pattern.
  • a detectably- labeled nucleic acid from a reference sample is hybridized to a second microarray comprising at least three nucleic acid probes from microbes selected from the group consisting of Adenoviridae, Anelloviridae, Arenaviridae, Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Herpesviridae, Iridoviridae, Papillomaviridae, Paramyxoviridae, Parvoviridae, Picornaviridae, Poxviridae, Reoviridae, Retroviridae and Rhabdoviridae, Actinomyces, Bartonella, Brevundimonas, Coxiella, Mobiluncus, Mycobacterium,
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared. When the first hybridization pattern is substantially a microbial hybridization signature and the second hybridization pattern is substantially not a microbial hybridization signature, breast cancer is detected in the tumor tissue sample.
  • Yet another aspect of the invention includes a method of detecting endocrine receptor positive breast cancer (BRER) in a tumor tissue sample from a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from the tumor tissue sample to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably-labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern.
  • the reference sample is from an otherwise identical non- tumor tissue from a subject.
  • the the first and second hybridization patterns are compared.
  • the probes are from microbes selected from the group consisting of: Arcanobacterium, Bifidobacterium, Cardiobacterium, Citrobacter, Escherichia, Filobasidiella, Mucor, Trichophyton, Brugia and Paragonimus
  • the second hybridization pattern is substantially not generated by hybridization of the detectably- labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Arcanobacterium, Bifidobacterium, Cardiobacterium, Citrobacter, Escherichia, Filobasidiella, Mucor, Trichophyton, Brugia and Paragonimus
  • BRER is detected in the tumor tissue sample.
  • Still another aspect of the invention includes a method of distinguishing BRER from human epidermal growth factor receptor 2 (HER2) positive breast cancer (BRHR), triple positive breast cancer (BRTP), and triple negative breast cancer (BRTN) in a tumor tissue sample from a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from the tumor tissue sample to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably-labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern.
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared.
  • the first hybridization pattern is generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Arcanobacterium, Bifidobacterium, Cardiobacterium, Citrobacter, Escherichia, Filobasidiella, Mucor, Trichophyton, Brugia and Paragonimus
  • the second hybridization pattern is substantially not generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Arcanobacterium, Bifidobacterium,
  • BRER is distinguished from BRHR, BRTP, and BRTN in the tumor tissue sample.
  • the invention includes a method of detecting BRHR in a tumor tissue sample from a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from the tumor tissue sample to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably-labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared.
  • the first hybridization pattern is generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Novaviridae, Streptococcus,
  • the second hybridization pattern is substantially not generated by hybridization of the detectably- labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Novaviridae, Streptococcus, Epidermophyton, Fonsecaea, Pseudallescheria, and Balamuthia, then BRHR is detected in the tumor tissue sample.
  • the invention includes a method of distinguishing BRHR from BRER, BRTP and BRTN in a tumor tissue sample from a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from the tumor tissue sample to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably-labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern.
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared.
  • the first hybridization pattern is generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Novaviridae,
  • the second hybridization pattern is substantially not generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Novaviridae, Streptococcus, Epidermophyton, Fonsecaea, Pseudallescheria, and Balamuthia, then BRHR is distinguished from BRER, BRTP, and BRTN in the tumor tissue sample.
  • the invention includes a method of detecting BRTP in a tumor tissue sample from a subject.
  • the method comprises hybridizing a detectably- labeled nucleic acid from the tumor tissue sample to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably-labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern.
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared.
  • the first hybridization pattern is generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Birnaviridae, Hepeviridae, Bordetella, Campylobacter, Chlamydia, Chlamydophila, Legionella, Pasteurella, Penicillium, Ancylostoma, Angiostrongylus, Echinococcus, Sarcocystis, Trichomonas, and
  • Trichostrongylus and the second hybridization pattern is substantially not generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Birnaviridae, Hepeviridae, Bordetella,
  • Trichostrongylus then BRTP is detected in the tumor tissue sample.
  • the invention includes a method of distinguishing BRTP from BRHR, BRER, and BRTN in a tumor tissue sample from a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from the tumor tissue sample to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably- labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern.
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared.
  • the first hybridization pattern is generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Birnaviridae, Hepeviridae, Bordetella, Campylobacter, Chlamydia, Chlamydophila, Legionella, Pasteurella, Penicillium, Ancylostoma, Angiostrongylus, Echinococcus, Sarcocystis,
  • Trichomonas Trichostrongylus
  • the second hybridization pattern is substantially not generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Birnaviridae, Hepeviridae, Bordetella, Campylobacter, Chlamydia, Chlamydophila, Legionella, Pasteurella,
  • BRTP is distinguished from BRHR, BRER, and BRTN in the tumor tissue sample.
  • Another aspect of the invention includes a method of distinguishing BRTN from BRHR, BRER, and BRTP in a tumor tissue sample from a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from the tumor tissue sample to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably-labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern.
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared.
  • the first hybridization pattern is generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Aerococcus,
  • BRTN is distinguished from BRHR, BRER, and BRTP in the tumor tissue sample.
  • kits comprising a microarray comprising at least three nucleic acid probes selected from the group of microbes consisting of Adenoviridae, Anelloviridae, Arenaviridae, Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Herpesviridae, Iridoviridae, Papillomaviridae, Paramyxoviridae, Parvoviridae, Picornaviridae, Poxviridae, Reoviridae, Retroviridae and Rhabdoviridae, Actinomyces, Bartonella, Brevundimonas, Coxiella, Mobiluncus, Mycobacterium,
  • Still another aspect of the invention includes a kit comprising a microarray comprising at least three nucleic acid probes selected from the group of microbes consisting of Arcanobacterium, Bifidobacterium, Cardiobacterium, Citrobacter,
  • Escherichia Filobasidiella, Mucor, Trichophyton, Brugia and Paragonimus, and instructional material for use thereof.
  • the invention includes a kit comprising a microarray comprising at least three nucleic acid probes selected from the group of microbes consisting of Novaviridae, Streptococcus, Epidermophyton, Fonsecaea, Pseudallescheria, and
  • the invention includes a kit comprising a microarray comprising at least three nucleic acid probes selected from the group of microbes consisting of Birnaviridae, Hepeviridae, Bordetella, Campylobacter, Chlamydia, Chlamydophila, Legionella, Pasteurella, Penicillium, Ancylostoma, Angiostrongylus, Echinococcus, Sarcocystis, Trichomonas, and Trichostrongylus, and instructional material for use thereof.
  • a microarray comprising at least three nucleic acid probes selected from the group of microbes consisting of Birnaviridae, Hepeviridae, Bordetella, Campylobacter, Chlamydia, Chlamydophila, Legionella, Pasteurella, Penicillium, Ancylostoma, Angiostrongylus, Echinococcus, Sarcocystis, Trichomonas, and Trichostrongylus, and instructional material
  • the invention includes a kit comprising a microarray comprising at least three nucleic acid probes selected from the group of microbes consisting of Aerococcus, Arcobacter, Geobacillus, Orientia and Rothia, Alternaria, Malassezia, Piedraia, Rhizomucor, Centrocestus, Contracaecum, Leishmania, Necator, Onchocerca, Toxocara, Trichinella, and Trichuris, and instructional material for use thereof.
  • a microarray comprising at least three nucleic acid probes selected from the group of microbes consisting of Aerococcus, Arcobacter, Geobacillus, Orientia and Rothia, Alternaria, Malassezia, Piedraia, Rhizomucor, Centrocestus, Contracaecum, Leishmania, Necator, Onchocerca, Toxocara, Trichinella, and Trichuris, and instructional material for use thereof.
  • Another aspect of the invention includes a method of detecting and treating breast cancer in a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from a tumor tissue sample from the subject to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably-labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern.
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared. When the first hybridization pattern is substantially a microbial hybridization signature and the second hybridization pattern is substantially not a microbial hybridization signature, then breast cancer is detected in the subject, and a treatment is administered to the subject.
  • Yet another aspect of the invention includes a method of detecting and treating breast cancer in a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from a tumor tissue sample from the subject to a first microarray comprising at least three nucleic acid probes from microbes selected from the group consisting of
  • Adenoviridae Anelloviridae, Arenaviridae, Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Herpesviridae, Iridoviridae, Papillomaviridae, Paramyxoviridae,
  • Parvoviridae Picornaviridae, Poxviridae, Reoviridae, Retroviridae and Rhabdoviridae, Actinomyces, Bartonella, Brevundimonas, Coxiella, Mobiluncus, Mycobacterium, Rickettsia and Sphingomonas to generate a first hybridization pattern.
  • a detectably- labeled nucleic acid from a reference sample is hybridized to a second microarray comprising at least three nucleic acid probes from microbes selected from the group consisting of Adenoviridae, Anelloviridae, Arenaviridae, Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Herpesviridae, Iridoviridae, Papillomaviridae, Paramyxoviridae, Parvoviridae, Picornaviridae, Poxviridae, Reoviridae, Retroviridae and Rhabdoviridae, Actinomyces, Bartonella, Brevundimonas, Coxiella, Mobiluncus, Mycobacterium, Rickettsia and Sphingomonas to generate a second hybridization pattern.
  • microbes selected from the group consisting of Adenoviridae, Anelloviridae, Arenavirid
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared.
  • breast cancer is detected in the subject, and a treatment is administered to the subject.
  • Still another aspect of the invention includes a method of detecting and treating BRER in a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from a tumor tissue sample from the subject to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably-labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern.
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared.
  • the first hybridization pattern is generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Arcanobacterium, Bifidobacterium, Cardiobacterium, Citrobacter, Escherichia, Filobasidiella, Mucor, Trichophyton, Brugia and Paragonimus
  • the second hybridization pattern is substantially not generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Arcanobacterium, Bifidobacterium,
  • the invention includes a method of detecting and treating BRHR in a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from a tumor tissue sample from the subject to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably-labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern.
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared.
  • the first hybridization pattern is generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Novaviridae, Streptococcus, Epidermophyton, Fonsecaea, Pseudallescheria, and Balamuthia
  • the second hybridization pattern is substantially not generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Novaviridae, Streptococcus, Epidermophyton, Fonsecaea, Pseudallescheria, and Balamuthia
  • BRHR is detected in the subject.
  • a treatment is then administered to the subject.
  • the invention includes a method of detecting and treating BRTP in a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from a tumor tissue sample from a subject to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably-labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern.
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared.
  • the first hybridization pattern is generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Birnaviridae, Hepeviridae, Bordetella, Campylobacter, Chlamydia, Chlamydophila, Legionella, Pasteurella, Penicillium, Ancylostoma, Angiostrongylus, Echinococcus, Sarcocystis, Trichomonas, and
  • Trichostrongylus and the second hybridization pattern is substantially not generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Birnaviridae, Hepeviridae, Bordetella,
  • Trichostrongylus then BRTP is detected in the subject. A treatment is then administered to the subject.
  • the microbial hybridization signature is generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip.
  • the probes are from microbes selected from the group consisting of: Adenoviridae, Anelloviridae, Arenaviridae, Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Herpesviridae, Iridoviridae, Papillomaviridae, Paramyxoviridae, Parvoviridae, Picornaviridae, Poxviridae, Reoviridae, Retroviridae and Rhabdoviridae, Actinomyces, Bartonella, Brevundimonas, Coxiella, Mobiluncus, Mycobacterium, Rickettsia and Sphingomonas.
  • the tumor tissue sample is selected from the group consisting of a biopsy, formalin-fixed, paraffin-embedded (FFPE) sample, or non-solid tumor.
  • FFPE paraffin-embedded
  • the detectably-labeled nucleic acid is labeled with a fluorophore, radioactive phosphate, biotin, or enzyme.
  • the fluorophore is Cy3 or Cy5.
  • the subject is human.
  • the subject when breast cancer is detected in the tumor tissue sample from a subject, the subject is provided with a treatment for breast cancer.
  • the treatment comprises surgery, chemotherapy, or radiotherapy.
  • the nucleic acid probes are selected from between about 10 to about 30 microbes and comprise about 3 to about 5 probes per microbe.
  • the microarray is a biochip, glass slide, bead, or paper.
  • FIGs. 1A-1E are a series of plots and images illustrating viral signatures associated with different breast cancer types.
  • FIG. 1 A is a Venn diagram showing the common and unique viral signatures in the 4 types of breast cancers.
  • FIG. IB is a heat map of common viral signatures in the 4 breast cancer types.
  • FIG. 1C shows relative hybridization signals of viral probes detected in breast cancer types. For example, hybridization signals for Polyomaviridae probes were 4%, 6% and 3% of the total hybridization signals detected in BRER, BRTP and BRHR respectively.
  • FIG. ID shows the prevalence of viral signatures in 4 breast cancer types.
  • FIG. IE shows a heat map of hybridization signals for viral signatures that are significantly higher in the cancers when compared to the control.
  • FIGs. 2A-2E are a series of plots and images illustrating bacterial signatures associated with different breast cancer types.
  • FIG. 2A shows bacterial phyla associated with breast cancer types.
  • FIG. 2B is a Venn diagram showing the common and unique bacterial signatures in the 4 types of breast cancers.
  • FIG. 2C is a heat map of common viral signatures in the 4 breast cancer types.
  • FIG. 2D shows hybridization signals of bacterial probes detected in breast cancer types.
  • FIG. 2E shows the prevalence of bacterial signatures in 4 breast cancer types.
  • FIGs 3A-3F are a series of graphs illustrating fungal and parasitic signatures associated with different breast cancer types.
  • FIG. 3A shows relative hybridization signals of fungal probes detected in breast cancer types. For example, hybridization signals for Ajellomyces were 7%, 8% and 14% of the total hybridization signals detected in BRER, BRTP and BRHR respectively, and that of Rhizomucor is 19% of the hybridization signals detected in BRTN.
  • FIG. 3B shows prevalence of viral signatures in
  • FIG. 3C is a Venn diagram showing the common and unique fungal signatures in the 4 types of breast cancers.
  • FIG. 3D shows relative hybridization signals of parasitic probes detected in breast cancer types.
  • hybridization signals for Plasmodium were 10%, 6% and 21% of the total hybridization signals detected in BRER, BRTP and BRHR respectively, and that of ' Mansonella is 7% and 12% of the
  • FIG. 3E shows prevalence of parasitic signatures in 4 breast cancer types.
  • FIG. 3F is a Venn diagram showing the common and unique parasitic signatures in the 4 types of breast cancers.
  • FIGs. 4A-4E are a series of plots illustrating hierarchical clustering of different breast cancer types based on their microbial signature detection pattern.
  • FIG. 4A shows clustering of BRER.
  • FIG. 4B shows clustering of BRTP.
  • FIG. 4C shows clustering of BRHR.
  • FIG. 4D shows clustering of BRTN.
  • FIG. 4E shows the comparison of the microbiome signatures from all four breast cancer types together in the clustering analysis.
  • FIGs. 5A-5B are a series of plots and images illustrating PCR validation of microbial signatures in the 4 types of breast cancers and non-matched control, using the primers from FIG. 13.
  • the left panels show the cropped gel pictures of EtBr stained amplicons run on agarose gel, where M is DNA ladder of Rsal digested ⁇ /174, NTC is non-template control.
  • the sequenced amplicons were subjected to nucleotide blast program in NCBI, and the results are shown in the right panels.
  • the reverse and the forward arrow heads signify Simian virus 40 and Merkel cell polyomavirus amplicons respectively, the electropherogram of the sequences of which are marked with the same arrow heads in FIGs. 6A-6B.
  • FIGs. 6A-6B are a series of images showing parts of the electropherograms of the sequenced amplicons validating the PathoChip screen results by PCR and Sanger sequencing.
  • FIG. 7 is a table displaying unique and common microbial signatures for 4 breast cancer types.
  • FIGs. 8A-8G are a series of tables showing the average hybridization signals of the probes of microorganisms detected in the cancers versus the controls, with respective adjusted p-values with multiple corrections.
  • FIGs. 8A-8B show average hybridization signals for BRER.
  • FIGs. 8C-8D show average hybridization signals for BRTP.
  • FIGs. 8E- 8F show average hybridization signals for BRHR.
  • FIG. 8G shows average hybridization signals for BRTN.
  • FIG. 9 is a table illustrating BRER cluster 1 vs 2 from FIG. 4E.
  • FIG. 10 is a set of tables displaying BRER Cluster 1ER vs. Ungrouped 1ER and BRER Cluster 2ER vs ungrouped 1ER from FIG. 4E.
  • FIG. 11 is a set of tables displaying BRHR ClusterlHR VS Ungrouped
  • FIG. 12 is a set of tables displaying BRTN Cluster 1TN VS ungrouped 1TN and BRTN Cluster 2TN VS ungrouped 1TN from FIG. 4D.
  • FIG. 13 is a table displaying the primers used for PCR validation of PathoChip screen (SEQ ID NOs: 1-16).
  • FIG. 14 is a table displaying BLAST results of the sequenced PCR products for the validation of PathoChip screen.
  • an element means one element or more than one element.
  • “About” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ⁇ 20% or ⁇ 10%, more preferably ⁇ 5%, even more preferably ⁇ 1%, and still more preferably ⁇ 0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
  • a “biomarker” or “marker” as used herein generally refers to a nucleic acid molecule, clinical indicator, protein, or other analyte that is associated with a disease.
  • a nucleic acid biomarker is indicative of the presence in a sample of a pathogenic organism, including but not limited to, viruses, viroids, bacteria, fungi, helminths, and protozoa.
  • a marker is differentially present in a biological sample obtained from a subject having or at risk of developing a disease (e.g., an infectious disease) relative to a reference.
  • a marker is differentially present if the mean or median level of the biomarker present in the sample is statistically different from the level present in a reference.
  • a reference level may be, for example, the level present in an environmental sample obtained from a clean or uncontaminated source.
  • a reference level may be, for example, the level present in a sample obtained from a healthy control subject or the level obtained from the subject at an earlier timepoint, i. e. , prior to treatment.
  • Common tests for statistical significance include, among others, t-test,
  • Biomarkers alone or in combination, provide measures of relative likelihood that a subject belongs to a phenotypic status of interest.
  • the differential presence of a marker of the invention in a subject sample can be useful in characterizing the subject as having or at risk of developing a disease (e.g., an infectious disease), for determining the prognosis of the subject, for evaluating therapeutic efficacy, or for selecting a treatment regimen.
  • a disease e.g., an infectious disease
  • agent any nucleic acid molecule, small molecule chemical compound, antibody, or polypeptide, or fragments thereof.
  • alteration or “change” is meant an increase or decrease. An alteration may be by as little as 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, or by 40%, 50%, 60%, or even by as much as 70%, 75%, 80%, 90%, or 100%.
  • biological sample any tissue, cell, fluid, or other material derived from an organism.
  • capture reagent is meant a reagent that specifically binds a nucleic acid molecule or polypeptide to select or isolate the nucleic acid molecule or polypeptide.
  • the terms “determining”, “assessing”, “assaying”, “measuring” and “detecting” refer to both quantitative and qualitative determinations, and as such, the term “determining” is used interchangeably herein with “assaying,” “measuring,” and the like. Where a quantitative determination is intended, the phrase “determining an amount” of an analyte and the like is used. Where a qualitative and/or quantitative determination is intended, the phrase “determining a level" of an analyte or “detecting” an analyte is used.
  • detectable moiety is meant a composition that when linked to a molecule of interest renders the latter detectable, via spectroscopic, photochemical, biochemical, immunochemical, or chemical means.
  • useful labels include radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron- dense reagents, enzymes (for example, as commonly used in an ELISA), biotin, digoxigenin, or haptens.
  • a “disease” is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal's health continues to deteriorate.
  • a “disorder” in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal's state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal's state of health.
  • results may include, but are not limited to, anti -tumor activity as determined by any means suitable in the art.
  • Encoding refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e. , rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom.
  • a gene encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system.
  • Both the coding strand the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA.
  • fragment is meant a portion of a nucleic acid molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides.
  • homologous refers to the subunit sequence identity between two polymeric molecules, e.g. , between two nucleic acid molecules, such as, two DNA molecules or two RNA molecules, or between two polypeptide molecules.
  • a subunit position in both of the two molecules is occupied by the same monomelic subunit; e.g. , if a position in each of two DNA molecules is occupied by adenine, then they are homologous at that position.
  • the homology between two sequences is a direct function of the number of matching or homologous positions; e.g. , if half (e.g. , five positions in a polymer ten subunits in length) of the positions in two sequences are homologous, the two sequences are 50% homologous; if 90% of the positions (e.g. , 9 of
  • Hybridization means hydrogen bonding, which may be Watson-Crick,
  • Hoogsteen or reversed Hoogsteen hydrogen bonding between complementary nucleobases.
  • adenine and thymine are complementary nucleotides that pair through the formation of hydrogen bonds.
  • Identity refers to the subunit sequence identity between two polymeric molecules particularly between two amino acid molecules, such as, between two polypeptide molecules.
  • two amino acid sequences have the same residues at the same positions; e.g. , if a position in each of two polypeptide molecules is occupied by an Arginine, then they are identical at that position.
  • the identity or extent to which two amino acid sequences have the same residues at the same positions in an alignment is often expressed as a percentage.
  • the identity between two amino acid sequences is a direct function of the number of matching or identical positions; e.g. , if half (e.g.
  • positions in two sequences are identical, the two sequences are 50% identical; if 90% of the positions (e.g., 9 of 10), are matched or identical, the two amino acids sequences are 90% identical.
  • an "instructional material” includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the compositions and methods of the invention.
  • the instructional material of the kit of the invention may, for example, be affixed to a container which contains the nucleic acid, peptide, and/or composition of the invention or be shipped together with a container which contains the nucleic acid, peptide, and/or composition.
  • the instructional material may be shipped separately from the container with the intention that the instructional material and the compound be used cooperatively by the recipient.
  • isolated refers to material that is free to varying degrees from components which normally accompany it as found in its native state.
  • Isolate denotes a degree of separation from original source or surroundings.
  • Purify denotes a degree of separation that is higher than isolation.
  • biologically pure protein is sufficiently free of other materials such that any impurities do not materially affect the biological properties of the protein or cause other adverse consequences. That is, a nucleic acid or peptide of this invention is purified if it is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Purity and homogeneity are typically determined using analytical chemistry techniques, for example, polyacrylamide gel electrophoresis or high performance liquid chromatography. The term “purified” can denote that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. For a protein that can be subjected to modifications, for example, phosphorylation or glycosylation, different modifications may give rise to different isolated proteins, which can be separately purified.
  • marker profile is meant a characterization of the signal, level, expression or expression level of two or more markers (e.g., polynucleotides).
  • microbe any and all organisms classed within the commonly used term “microbiology,” including but not limited to, bacteria, viruses, fungi and parasites.
  • microarray is meant a collection of nucleic acid probes immobilized on a substrate.
  • nucleic acid refers to deoxyribonucleotides, ribonucleotides, or modified nucleotides, and polymers thereof in single- or double- stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non- naturally occurring.
  • Nucleic acid molecules useful in the methods of the invention include any nucleic acid molecule that specifically binds a target nucleic acid (e.g., a nucleic acid biomarker). Such nucleic acid molecules need not be 100% identical with an endogenous nucleic acid sequence, but will typically exhibit substantial identity.
  • Polynucleotides having "substantial identity" to an endogenous sequence are typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule.
  • hybridize is meant pair to form a double-stranded molecule between complementary polynucleotide sequences (e.g., a gene described herein), or portions thereof, under various conditions of stringency.
  • complementary polynucleotide sequences e.g., a gene described herein
  • moduleating mediating a detectable increase or decrease in the level of a response in a subject compared with the level of a response in the subject in the absence of a treatment or compound, and/or compared with the level of a response in an otherwise identical but untreated subject.
  • the term encompasses perturbing and/or affecting a native signal or response thereby mediating a beneficial therapeutic response in a subject, preferably, a human.
  • A refers to adenosine
  • C refers to cytosine
  • G refers to guanosine
  • T refers to thymidine
  • U refers to uridine.
  • parenteral administration of an immunogenic composition includes, e.g. , subcutaneous (s.c), intravenous (i.v.), intramuscular (i.m.), or intrasternal injection, or infusion techniques.
  • polypeptide As used herein, the terms “peptide,” “polypeptide,” and “protein” are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds.
  • a protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that can comprise a protein's or peptide's sequence.
  • Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types.
  • Polypeptides include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified
  • polypeptides derivatives, analogs, fusion proteins, among others.
  • the polypeptides include natural peptides, recombinant peptides, synthetic peptides, or a combination thereof.
  • the level of a target nucleic acid molecule present in a sample may be compared to the level of the target nucleic acid molecule present in a clean or uncontaminated sample.
  • the level of a target nucleic acid molecule present in a sample may be compared to the level of the target nucleic acid molecule present in a corresponding healthy cell or tissue or in a diseased cell or tissue
  • a cell or tissue derived from a subject having a disease, disorder, or condition e.g., a cell or tissue derived from a subject having a disease, disorder, or condition.
  • sample includes a biologic sample such as any tissue, cell, fluid, or other material derived from an organism.
  • telomere binding binds is meant a compound (e.g., nucleic acid probe or primer) that recognizes and binds a molecule (e.g. , a nucleic acid biomarker), but which does not substantially recognize and bind other molecules in a sample, for example, a biological sample.
  • a compound e.g., nucleic acid probe or primer
  • a molecule e.g. , a nucleic acid biomarker
  • substantially identical is meant a polypeptide or nucleic acid molecule exhibiting at least 50% identity to a reference amino acid sequence (for example, any one of the amino acid sequences described herein) or nucleic acid sequence (for example, any one of the nucleic acid sequences described herein).
  • a reference amino acid sequence for example, any one of the amino acid sequences described herein
  • nucleic acid sequence for example, any one of the nucleic acid sequences described herein.
  • such a sequence is at least 60%, more preferably 80% or 85%, and more preferably 90%, 95%, 96%, 97%, 98%, or even 99% or more identical at the amino acid level or nucleic acid to the sequence used for comparison.
  • Sequence identity is typically measured using sequence analysis software (for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, BESTFIT, GAP, or PILEUP/PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and/or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. In an exemplary approach to determining the degree of identity, a BLAST program may be used, with a probability score between e "3 and e "100 indicating a closely related sequence.
  • sequence analysis software for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology
  • substantially microbial hybridization signature is a relative term and means a hybridization signature that indicates the presence of more microbes in a tumor sample than in a reference sample.
  • substantially not a microbial hybridization signature is a relative term and means a hybridization signature that indicates the presence of less microbes in a reference sample than in a tumor sample.
  • subject is meant a mammal, including, but not limited to, a human or non- human mammal, such as a bovine, equine, canine, ovine, feline, mouse, or monkey.
  • subject may refer to an animal, which is the object of treatment, observation, or experiment (e.g., a patient).
  • target nucleic acid molecule is meant a polynucleotide to be analyzed. Such polynucleotide may be a sense or antisense strand of the target sequence.
  • target nucleic acid molecule also refers to amplicons of the original target sequence.
  • the target nucleic acid molecule is one or more nucleic acid biomarkers.
  • target site or “target sequence” refers to a genomic nucleic acid sequence that defines a portion of a nucleic acid to which a binding molecule may specifically bind under conditions sufficient for binding to occur.
  • terapéutica as used herein means a treatment and/or prophylaxis.
  • a therapeutic effect is obtained by suppression, remission, or eradication of a disease state.
  • treat refers to reducing or ameliorating a disorder and/or symptoms associated therewith. It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated.
  • tumor tissue sample any sample from a tumor in a subject including any solid and non-solid tumor in the subject.
  • the present invention features compositions and methods for the detection or diagnosis of breast cancer in a subject.
  • the invention also features methods and kits for detecting specific types of breast cancer including endocrine receptor (estrogen or progesterone receptor) positive (BRER), human epidermal growth factor receptor 2 (HER2) positive (BRHR), triple positive (estrogen, progesterone and HER2 receptor positive) (BRTP) and triple negative (absence of estrogen, progesterone and HER2 receptors) (BRTN), and for distinguishing the different types of breast cancer from one another.
  • endocrine receptor (estrogen or progesterone receptor) positive BRER
  • HER2 human epidermal growth factor receptor 2
  • BRTP triple positive
  • BRTN triple negative (absence of estrogen, progesterone and HER2 receptors)
  • Metagenomic signatures from a number of viral, bacterial, fungal, and parasitic microbes were identified herein that indicate that a subject has breast cancer, and determines the specific type of breast cancer (BRER, BRHR, BRTP, or BRTN).
  • the raicrobiome potentially has a role in the pathogenesis of many different diseases including cancer.
  • Breast cancer is the second leading cause of cancer death in women, thus the diversity of the microbiome in four different types of breast cancer was investigated herein: endocrine receptor (ER) positive, triple positive, Her2 positive and triple negative breast cancers.
  • ER endocrine receptor
  • Her2 positive and triple negative breast cancers Using whole genome and transcriptome amplification and a pan-pathogen microarray (PathoChip), unique and common viral, bacterial, fungal and parasitic signatures were detected for each of the breast cancer types. Validation was provided by PCR. and Sanger sequencing.
  • Hierarchical cluster analysis of the breast cancer samples showed distinct signature patterns tor the triple negative and triple positive samples, while the ER positive and Her2 positive samples shared similar microbiome signatures. These signatures, unique or common to the different breast cancer types, provide a new line of investigation to gain insight into prognosis, treatment strategies and clinical outcome, as well as better understanding of the role of the microbiome in the development and progression of breast cancer.
  • the present invention includes methods of detecting breast cancer in a tumor tissue sample from a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from the tumor tissue sample to a PathoChip array to generate a first hybridization pattern, then hybridizing a detectably-labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern.
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared. When the first hybridization pattern is substantially a microbial hybridization signature and the second hybridization pattern is substantially not a microbial hybridization signature, breast cancer is detected in the tumor tissue sample.
  • the method comprises wherein the microbial hybridization signature is generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of:
  • Adenoviridae Anelloviridae, Arenaviridae, Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Herpesviridae, Iridoviridae, Papillomaviridae, Paramyxoviridae,
  • Parvoviridae Picornaviridae, Poxviridae, Reoviridae, Retroviridae and Rhabdoviridae, Actinomyces, Bartonella, Brevundimonas, Coxiella, Mobiluncus, Mycobacterium, Rickettsia and Sphingomonas.
  • Another aspect of the invention includes a method of detecting breast cancer in a tumor tissue sample from a subject comprising hybridizing a detectably-labeled nucleic acid from the tumor tissue sample to a first microarray.
  • the first microarray comprises at least three nucleic acid probes from microbes selected from the group consisting of Adenoviridae, Anelloviridae, Arenaviridae, Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Herpesviridae, Iridoviridae, Papillomaviridae, Paramyxoviridae,
  • a first hybridization pattern is generated. Then, hybridizing a detectably-labeled nucleic acid from a reference sample to a second microarray.
  • the second microarray comprises at least three nucleic acid probes from microbes selected from the group consisting of Adenoviridae, Anelloviridae,
  • Arenaviridae Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Herpesviridae, Iridoviridae, Papillomaviridae, Paramyxoviridae, Parvoviridae, Picornaviridae,
  • a second hybridization pattern is generated.
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared. When the first hybridization pattern is substantially a microbial hybridization signature and the second hybridization pattern is substantially not a microbial hybridization signature, breast cancer is detected in the tumor tissue sample.
  • the invention includes a method of detecting endocrine receptor positive breast cancer (BRER) in a tumor tissue sample from a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from the tumor tissue sample to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably- labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern.
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared.
  • the first hybridization pattern is generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of:
  • Arcanobacterium Bifidobacterium, Cardiobacterium, Citrobacter, Escherichia,
  • the second hybridization pattern is substantially not generated by hybridization of the detectably- labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Arcanobacterium, Bifidobacterium, Cardiobacterium, Citrobacter, Escherichia, Filobasidiella, Mucor, Trichophyton, Brugia and Paragonimus, then BRER is detected in the tumor tissue sample.
  • the invention includes a method of distinguishing BRER from human epidermal growth factor receptor 2 (HER2) positive breast cancer (BRHR), triple positive breast cancer (BRTP), and triple negative breast cancer (BRTN) in a tumor tissue sample from a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from the tumor tissue sample to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably-labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern.
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared.
  • the first hybridization pattern is generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Arcanobacterium, Bifidobacterium, Cardiobacterium, Citrobacter, Escherichia, Filobasidiella, Mucor, Trichophyton, Brugia and Paragonimus
  • the second hybridization pattern is substantially not generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Arcanobacterium, Bifidobacterium,
  • BRER is distinguished from BRHR, BRTP, and BRTN in the tumor tissue sample.
  • Another aspect of the invention includes a method of detecting human epidermal growth factor receptor 2 (HER2) positive breast cancer (BRHR) in a tumor tissue sample from a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from the tumor tissue sample to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably-labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern, wherein the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared.
  • the first hybridization pattern is generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Novaviridae, Streptococcus, Epidermophyton, Fonsecaea, Pseudallescheria, and Balamuthia
  • the second hybridization pattern is substantially not generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Novaviridae, Streptococcus, Epidermophyton, Fonsecaea, Pseudallescheria, and Balamuthia
  • BRHR is detected in the tumor tissue sample.
  • Yet another aspect of the invention includes a method of distinguishing BRHR from BRER, BRTP and BRTN in a tumor tissue sample from a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from the tumor tissue sample to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably- labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern, wherein the reference sample is from an otherwise identical non- tumor tissue from a subject.
  • the first and second hybridization patterns are compared.
  • the first hybridization pattern is generated by hybridization of the detectably- labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Novaviridae, Streptococcus, Epidermophyton, Fonsecaea, Pseudallescheria, and Balamuthia
  • the second hybridization pattern is substantially not generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Novaviridae, Streptococcus, Epidermophyton,
  • BRHR is distinguished from BRER, BRTP, and BRTN in the tumor tissue sample.
  • Still another aspect of the invention includes a method of detecting BRTP in a tumor tissue sample from a subject.
  • the method comprises hybridizing a detectably- labeled nucleic acid from the tumor tissue sample to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably-labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern, wherein the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared.
  • the first hybridization pattern is generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Birnaviridae, Hepeviridae, Bordetella, Campylobacter, Chlamydia, Chlamydophila, Legionella, Pasteurella, Penicillium, Ancylostoma, Angiostrongylus, Echinococcus, Sarcocystis, Trichomonas, and
  • the second hybridization pattern is substantially not generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Birnaviridae, Hepeviridae, Bordetella, Campylobacter, Chlamydia, Chlamydophila, Legionella, Pasteurella, Penicillium, Ancylostoma, Angiostrongylus, Echinococcus, Sarcocystis, Trichomonas, and
  • Trichostrongylus then BRTP is detected in the tumor tissue sample.
  • Another aspect of the invention includes a method of distinguishing BRTP from BRHR, BRER, and BRTN in a tumor tissue sample from a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from the tumor tissue sample to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably- labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern.
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared.
  • the first hybridization pattern is generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Birnaviridae, Hepeviridae, Bordetella, Campylobacter, Chlamydia, Chlamydophila, Legionella, Pasteurella, Penicillium, Ancylostoma, Angiostrongylus, Echinococcus, Sarcocystis,
  • Trichomonas Trichostrongylus
  • the second hybridization pattern is substantially not generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Birnaviridae, Hepeviridae, Bordetella, Campylobacter, Chlamydia, Chlamydophila, Legionella, Pasteurella,
  • BRTP is distinguished from BRHR, BRER, and BRTN in the tumor tissue sample.
  • the invention includes a method of distinguishing BRTN from BRHR, BRER, and BRTP in a tumor tissue sample from a subject.
  • the method comprises hybridizing a detectably-labeled nucleic acid from the tumor tissue sample to a PathoChip array to generate a first hybridization pattern and hybridizing a detectably-labeled nucleic acid from a reference sample to a PathoChip array to generate a second hybridization pattern.
  • the reference sample is from an otherwise identical non-tumor tissue from a subject.
  • the first and second hybridization patterns are compared.
  • the first hybridization pattern is generated by hybridization of the detectably-labeled nucleic acid from the tumor tissue sample to at least three nucleic acid probes on the PathoChip, wherein the probes are from microbes selected from the group consisting of: Aerococcus, Arcobacter, Geobacillus, Orientia and Rothia, Alternaria, Malassezia, Piedraia,
  • BRTN is distinguished from BRHR, BRER, and BRTP in the tumor tissue sample.
  • the tumor tissue sample can be a biopsy, formalin-fixed, paraffin-embedded (FFPE) sample, or non-solid tumor.
  • the detectably- labeled nucleic acid can be labeled with a fluorophore, radioactive phosphate, biotin, or enzyme and the fluorophore can be Cy3 or Cy5.
  • the methods can also include providing the subject with a treatment for breast cancer, when breast cancer is detected in the tumor tissue sample from the subject.
  • a treatment for breast cancer includes all types of breast cancer including but not limited to BRTN, BRTP, BRER, and BRHR.
  • treatments include, but are not limited to, surgery, chemotherapy, or radiotherapy.
  • the subject can be any human or non-human mammal, such as a bovine, equine, canine, ovine, feline, mouse, or monkey. In one embodiment, the subject is a human.
  • kits for the detection of biomarkers which are indicative of the presence of one or more biological sequences or agents associated with breast cancer.
  • the kits may be used for detecting the presence of multiple biological agents associated with breast cancer.
  • the kits may be used for the diagnosis or detection of different types of breast cancer.
  • the kit comprises a panel or collection of probes to nucleic acid biomarkers (e.g., PathoChip) delineated herein as specific for detection of breast cancer.
  • the kit comprises a panel or collection of probes to nucleic acid biomarkers (e.g., PathoChip) delineated herein as specific for detection of a specific type of breast cancer (BRTN, BRTP, BRER, and BRHR).
  • the kit comprises an antibody specific for a pathogenic organism associated with breast cancer.
  • antibodies may be used for ELISA detection or for extraction of a pathogenic organism associated with breast cancer (e.g., a biotin labeled antibody in conjunction with Streptavidin bound magnetic beads).
  • the kit comprises one or more sterile containers which contain the panel of probes, nucleic acid biomarkers, or a microarray.
  • sterile containers which contain the panel of probes, nucleic acid biomarkers, or a microarray.
  • Such containers can be boxes, ampoules, bottles, vials, tubes, bags, pouches, blister-packs, or other suitable container forms known in the art.
  • Such containers can be made of plastic, glass, laminated paper, metal foil, or other materials suitable for holding medicaments.
  • the instructions will generally include information about the use of the composition for the detection or diagnosis of breast cancer or a specific type of breast cancer (i.e. BRTN, BRTP, BRER, and BRHR).
  • the instructions include at least one of the following: description of the therapeutic agent; dosage schedule and administration for treatment or prevention of breast cancer or symptoms thereof; precautions; warnings; indications; counter-indications; overdosage information; adverse reactions; animal pharmacology; clinical studies; and/or references.
  • the instructions may be printed directly on the container (when present), or as a label applied to the container, or as a separate sheet, pamphlet, card, or folder supplied in or with the container.
  • kits comprising a microarray comprising at least three nucleic acid probes selected from the group of microbes consisting of Adenoviridae, Anelloviridae, Arenaviridae, Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Herpesviridae, Iridoviridae, Papillomaviridae, Paramyxoviridae,
  • Parvoviridae Picornaviridae, Poxviridae, Reoviridae, Retroviridae and Rhabdoviridae, Actinomyces, Bartonella, Brevundimonas, Coxiella, Mobiluncus, Mycobacterium, Rickettsia and Sphingomonas, and instructional material for use thereof.
  • kits comprising a microarray comprising at least three nucleic acid probes selected from the group of microbes consisting of
  • Arcanobacterium Bifidobacterium, Cardiobacterium, Citrobacter, Escherichia,
  • kits comprising a microarray comprising at least three nucleic acid probes selected from the group of microbes consisting of Novaviridae, Streptococcus, Epidermophyton, Fonsecaea, Pseudallescheria, and Balamuthia, and instructional material for use thereof.
  • Still another aspect includes a kit comprising a microarray comprising at least three nucleic acid probes selected from the group of microbes consisting of Birnaviridae, Hepeviridae, Bordetella, Campylobacter, Chlamydia, Chlamydophila, Legionella, Pasteurella, Penicillium, Ancylostoma, Angiostrongylus, Echinococcus, Sarcocystis, Trichomonas, and Trichostrongylus, and instructional material for use thereof.
  • a microarray comprising at least three nucleic acid probes selected from the group of microbes consisting of Birnaviridae, Hepeviridae, Bordetella, Campylobacter, Chlamydia, Chlamydophila, Legionella, Pasteurella, Penicillium, Ancylostoma, Angiostrongylus, Echinococcus, Sarcocystis, Trichomonas, and Trichostrongylus, and instructional
  • kits comprising a microarray comprising at least three nucleic acid probes selected from the group of microbes consisting of Aerococcus, Arcobacter, Geobacillus, Orientia and Rothia, Alternaria, Malassezia, Piedraia, Rhizomucor, Centrocestus, Contracaecum, Leishmania, Necator, Onchocerca, Toxocara, Trichinella, and Trichuris, and instructional material for use thereof.
  • a microarray comprising at least three nucleic acid probes selected from the group of microbes consisting of Aerococcus, Arcobacter, Geobacillus, Orientia and Rothia, Alternaria, Malassezia, Piedraia, Rhizomucor, Centrocestus, Contracaecum, Leishmania, Necator, Onchocerca, Toxocara, Trichinella, and Trichuris, and instructional material for use thereof.
  • the kit can include probes from about 10-30 organisms with about 3-5 probes per organism.
  • the microarray in the kit comprises is a biochip, glass slide, bead, or paper.
  • compositions and methods of the invention are useful for the identification of a target nucleic acid molecule in a biological sample to be analyzed.
  • Target sequences are amplified from any biological sample that comprises a target nucleic acid molecule.
  • Such samples may comprise fungi, spores, viruses, or cells (e.g., prokaryotes, eukaryotes, including human).
  • Such samples may comprise viral, bacterial, fungal, and parasitic nucleic acid molecules.
  • compositions and methods of the invention detect one or more nucleic acid sequences from one or more pathogenic organisms, including viruses, viroids, bacteria, fungi, helminths, and/or protozoa.
  • a sample is a biological sample, such as a tissue or tumor sample.
  • the level of one or more polynucleotide biomarkers e.g., to detect or identify viruses, viroids, bacteria, fungi, helminths, and/or protozoa
  • the biological sample is a tissue sample that includes a tumor cell, for example, from a biopsy or formalin-fixed, paraffin-embedded (FFPE) sample.
  • FFPE formalin-fixed, paraffin-embedded
  • Exemplary test samples also include body fluids (e.g.
  • a target nucleic acid of a pathogen is amplified by primer
  • oligonucleotides to detect the presence of the nucleic acid sequence of an infectious agent in the sample.
  • nucleic acid sequences may derive from pathogens including fungi, bacteria, viruses and yeast.
  • Target nucleic acid molecules include double-stranded and single- stranded nucleic acid molecules (e.g., DNA, RNA, and other nucleobase polymers known in the art capable of hybridizing with a nucleic acid molecule described herein).
  • primer/template oligonucleotide of the invention include, but are not limited to, double- stranded and single-stranded RNA molecules that comprise a target sequence (e.g., messenger RNA, viral RNA, ribosomal RNA, transfer RNA, microRNA and microRNA precursors, and siRNAs or other RNAs described herein or known in the art).
  • a target sequence e.g., messenger RNA, viral RNA, ribosomal RNA, transfer RNA, microRNA and microRNA precursors, and siRNAs or other RNAs described herein or known in the art.
  • primer/template oligonucleotide of the invention include, but are not limited to, double stranded DNA (e.g., genomic DNA, plasmid DNA, mitochondrial DNA, viral DNA, and synthetic double stranded DNA).
  • Single-stranded DNA target nucleic acid molecules include, for example, viral DNA, cDNA, and synthetic single- stranded DNA, or other types of DNA known in the art.
  • a target sequence for detection is between about 30 and about 300 nucleotides in length (e.g., 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240,
  • the target sequence is about 60 nucleotides in length.
  • a target sequence for detection may also have at least about 70, 80, 90, 95, 96, 97, 98, 99, or even 100% identity to a probe sequence.
  • Probe sequences may be longer or shorter than the target sequence.
  • a 60- nucleotide probe may hybridize to at least about 44 nucleotides of a target sequence.
  • a biomarker is a biomolecule (e.g., nucleic acid molecule) that is differentially present in a biological sample.
  • a biomarker is taken from a subject of one phenotypic status (e.g., having breast cancer) as compared with another phenotypic status (e.g., not having breast cancer).
  • a biomarker is differentially present between different phenotypic statuses if the mean or median expression level of the biomarker in the different groups is calculated to be statistically significant. Common tests for statistical significance include, among others, t-test, ANOVA, Kruskal-Wallis, Wilcoxon, Mann-Whitney and odds ratio.
  • Biomarkers, alone or in combination provide measures of relative risk that a subject belongs to one phenotypic status or another. Therefore, they are useful as markers for characterizing a disease (e.g., having breast cancer).
  • sample preparation involves extracting a mixture of nucleic acid molecules (e.g., DNA and RNA).
  • sample preparation involves extracting a mixture of nucleic acids from multiple organisms, cell types, infectious agents, or any combination thereof.
  • sample preparation involves the workflow below.
  • microarray e.g., PathoChip
  • the samples are hybridized to the microarray (e.g., PathoChip), and the microarrays are washed at various stringencies.
  • Microarrays are scanned for detection of fluorescence. Background correction and inter-array normalization algorithms are applied. Detection thresholds are applied. The results are analyzed for statistical significance.
  • Target nucleic acid sequences are optionally amplified before being detected.
  • amplified defines the process of making multiple copies of the nucleic acid from a single or lower copy number of nucleic acid sequence molecule.
  • the amplification of nucleic acid sequences is carried out in vitro by biochemical processes known to those of skill in the art.
  • the viral sample Prior to or concurrent with identification, the viral sample may be amplified by a variety of mechanisms, some of which may employ PCR.
  • primers for PCR may be designed to amplify regions of the sequence.
  • RNA viruses a first reverse transcriptase step may be used to generate double stranded DNA from the single stranded RNA. See, for example, PCR Technology: Principles and Applications for DNA Amplification (Ed. H A. Erlich, Freeman Press, NY, N.Y., 1992); PCR
  • the sample may be amplified on the array. See, for example, US Patent No 6,300,070 and US Ser No 09/513,300.
  • LCR ligase chain reaction
  • LCR ligase chain reaction
  • Landegren et al. Science 241, 1077 (1988) and Barringer et al. Gene 89: 117 (1990)
  • transcription amplification Kwoh et al, Proc. Natl. Acad. Sci. USA 86, 1 173 (1989) and WO88/10315
  • self-sustained sequence replication Guatelli et al., Proc. Nat. Acad. Sci. USA, 87, 1874 (1990) and
  • biomarkers of this invention can be detected by any suitable method.
  • the methods described herein can be used individually or in combination for a more accurate detection of the biomarkers.
  • Methods for conducting polynucleotide hybridization assays have been developed in the art. Hybridization assay procedures and conditions will vary depending on the application and are selected in accordance with the general binding methods known including those referred to in: Sambrook and Russell, Molecular
  • the hybridized nucleic acids are detected by detecting one or more labels attached to, or incorporated within, the sample nucleic acids.
  • the labels may be attached or incorporated by any of a number of means well known to those of skill in the art.
  • the label is simultaneously incorporated during the amplification step in the preparation of the sample nucleic acids.
  • PCR with labeled primers or labeled nucleotides will provide a labeled amplification product.
  • transcription amplification as described above, using a labeled nucleotide (e.g. fluorescein-labeled UTP and/or CTP) incorporates a label into the transcribed nucleic acids.
  • a labeled nucleotide e.g. fluorescein-labeled UTP and/or CTP
  • PCR amplification products are fragmented and labeled by terminal deoxytransferase and labeled dNTPs.
  • a label may be added directly to the original nucleic acid sample (e.g., mRNA, polyA mRNA, cDNA, etc.) or to the amplification product after the amplification is completed.
  • Means of attaching labels to nucleic acids are well known to those of skill in the art and include, for example, nick translation or end-labeling (e.g. with a labeled RNA) by kinasing the nucleic acid and subsequent attachment (ligation) of a nucleic acid linker joining the sample nucleic acid to a label (e.g., a fluorophore).
  • label is added to the end of fragments using terminal deoxytransferase.
  • Detectable labels suitable for use in the present invention include any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means.
  • Useful labels in the present invention include, but are not limited to: biotin for staining with labeled streptavidin conjugate; anti-biotin antibodies, magnetic beads (e.g., DynabeadsTM.); fluorescent dyes (e.g., Cy3, Cy5, fluorescein, texas
  • radiolabels e.g., H, I, S, C, or 32 P
  • phosphorescent labels e.g., enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA); and colorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads.
  • Patents teaching the use of such labels include US Patent Nos 3,817,837, 3,850,752, 3,939,350, 3,996,345, 4,277,437, 4,275, 149 and 4,366,241.
  • radiolabels may be detected using photographic film or scintillation counters; fluorescent markers may be detected using a photodetector to detect emitted light.
  • Enzymatic labels are typically detected by providing the enzyme with a substrate and detecting the reaction product produced by the action of the enzyme on the substrate, and calorimetric labels are detected by simply visualizing the colored label.
  • a sample is analyzed by means of a microarray.
  • the nucleic acid molecules of the invention are useful as hybridizable array elements in a microarray.
  • Microarrays generally comprise solid substrates and have a generally planar surface, to which a capture reagent (also called an adsorbent or affinity reagent) is attached.
  • a capture reagent also called an adsorbent or affinity reagent
  • the surface of a biochip comprises a plurality of addressable locations, each of which has the capture reagent bound there.
  • the array elements are organized in an ordered fashion such that each element is present at a specified location on the substrate.
  • Useful substrate materials include membranes, composed of paper, nylon or other materials, filters, chips, glass slides, and other solid supports.
  • nucleic acid microarrays are known to the skilled artisan and are described, for example, in U.S. Pat. No. 5,837,832, Lockhart, et al. (Nat. Biotech. 14: 1675-1680, 1996), and Schena, et al. (Proc. Natl. Acad. Sci. 93 : 10614- 10619, 1996), herein incorporated by reference.
  • US Patent Nos 5,800,992 and 6,040, 138 describe methods for making arrays of nucleic acid probes that can be used to detect the presence of a nucleic acid containing a specific nucleotide sequence. Methods of forming high- density arrays of nucleic acids, peptides and other polymer sequences with a minimal number of synthetic steps are known.
  • the nucleic acid array can be synthesized on a solid substrate by a variety of methods, including, but not limited to, light-directed chemical coupling, and mechanically directed coupling.
  • light-directed chemical coupling and mechanically directed coupling.
  • hybridize pair to form a double-stranded molecule between complementary polynucleotide sequences (e.g., a gene described herein), or portions thereof, under various conditions of stringency.
  • complementary polynucleotide sequences e.g., a gene described herein
  • stringency See, e.g., Wahl, G. M. and S. L. Berger (1987) Methods Enzymol. 152:399; Kimmel, A. R. (1987) Methods Enzymol. 152:507).
  • stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and more preferably less than about 250 mM NaCl and 25 mM trisodium citrate.
  • Low stringency hybridization can be obtained in the absence of organic solvent, e.g. , formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and more preferably at least about 50% formamide.
  • Stringent temperature conditions will ordinarily include temperatures of at least about 30° C, more preferably of at least about 37° C, and most preferably of at least about 42° C. Varying additional parameters, such as hybridization time, the
  • hybridization will occur at 30° C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37° C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 Mg ml denatured salmon sperm DNA (ssDNA).
  • SDS sodium dodecyl sulfate
  • hybridization will occur at 42° C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 ⁇ g/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.
  • wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature.
  • stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate.
  • Stringent temperature conditions for the wash steps will ordinarily include a temperature of at least about 25° C, more preferably of at least about 42° C, and even more preferably of at least about 68° C
  • wash steps will occur at 25° C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS.
  • wash steps will occur at 42° C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS.
  • wash steps will occur at 68° C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art. Hybridization techniques are well known to those skilled in the art and are described, for example, in Benton and Davis (Science 196: 180, 1977);
  • the microarray comprises at least three nucleic acid probes selected from the group of microbes consisting of Adenoviridae, Anelloviridae, Arenaviridae, Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Herpesviridae, Iridoviridae, Papillomaviridae, Paramyxoviridae, Parvoviridae, Picornaviridae, Poxviridae, Reoviridae, Retroviridae and Rhabdoviridae, Actinomyces, Bartonella, Brevundimonas, Coxiella, Mobiluncus, Mycobacterium, Rickettsia and Sphingomonas.
  • the microarray comprises at least three nucleic acid probes selected from the group of microbes consisting of Arcanobacterium, Bifidobacterium, Cardiobacter
  • the microarray comprises at least three nucleic acid probes selected from the group of microbes consisting of Novaviridae, Streptococcus, Epidermophyton,
  • the microarray comprises at least three nucleic acid probes selected from the group of microbes consisting of Birnaviridae, Hepeviridae, Bordetella, Campylobacter, Chlamydia,
  • the microarray comprising at least three nucleic acid probes selected from the group of microbes consisting of Aerococcus, Arcobacter, Geobacillus, Orientia and Rothia, Alternaria, Malassezia, Piedraia, Rhizomucor, Centrocestus, Contracaecum, Leishmania,
  • the microarray can be a biochip, or on a glass slide, bead, or paper.
  • the nucleic acid probes can be selected from between about 10 to about 30 microbes and comprise about 3 to about 5 probes per microbe.
  • a sample is analyzed by means of a nucleic acid biochip (also known as a nucleic acid microarray).
  • a nucleic acid biochip also known as a nucleic acid microarray.
  • oligonucleotides may be synthesized or bound to the surface of a substrate using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251 1 16 (Baldeschweiler et al).
  • a gridded array may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedure.
  • nucleic acid molecules useful in the invention include polynucleotides that specifically bind nucleic acid biomarkers to one or more pathogenic organisms, and fragments thereof.
  • a nucleic acid molecule derived from a biological sample may be used to produce a hybridization probe as described herein.
  • the biological samples are generally derived from a patient, e.g. , as a bodily fluid (such as blood, blood serum, plasma, saliva, urine, ascites, cyst fluid, and the like); a homogenized tissue sample (e.g. , a tissue sample obtained by biopsy); or a cell or population of cells isolated from a patient sample. For some applications, cultured cells or other tissue preparations may be used.
  • the mR A is isolated according to standard methods, and cDNA is produced and used as a template to make complementary RNA suitable for hybridization. Such methods are well known in the art.
  • the RNA is amplified in the presence of fluorescent nucleotides, and the labeled probes are then incubated with the microarray to allow the probe sequence to hybridize to complementary oligonucleotides bound to the biochip.
  • Incubation conditions are adjusted such that hybridization occurs with precise complementary matches or with various degrees of less complementarity depending on the degree of stringency employed.
  • stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, less than about 500 mM NaCl and 50 mM trisodium citrate, or less than about 250 mM NaCl and 25 mM trisodium citrate.
  • Low stringency hybridization can be obtained in the absence of organic solvent, e.g. , formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and most preferably at least about 50% formamide.
  • Stringent temperature conditions will ordinarily include temperatures of at least about 30°C, of at least about 37°C, or of at least about 42°C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g. , sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In a preferred embodiment, hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS.
  • SDS sodium dodecyl sulfate
  • hybridization will occur at 37°C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 ⁇ g/ml denatured salmon sperm DNA (ssDNA). In other embodiments, hybridization will occur at 42°C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 ⁇ g/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.
  • wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature.
  • stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate.
  • Stringent temperature conditions for the wash steps will ordinarily include a temperature of at least about 25 °C, of at least about 42°C, or of at least about 68°C.
  • wash steps will occur at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 42 C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In other embodiments, wash steps will occur at 68 C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art.
  • Detection systems for measuring the absence, presence, and amount of hybridization for all of the distinct nucleic acid sequences are well known in the art. For example, simultaneous detection is described in Heller et al., Proc. Natl. Acad. Sci. 94:2150-2155, 1997.
  • a scanner is used to determine the levels and patterns of fluorescence.
  • the present invention provides a number of diagnostic assays that are useful for the identification or characterization of a disease or disorder (e.g., breast cancer), or a propensity to develop such a condition.
  • a disease or disorder e.g., breast cancer
  • a propensity to develop such a condition e.g., breast cancer
  • biomarkers characterized by quantifying the level of one or more biomarkers from one or more organisms, including viruses, viroids, bacteria, fungi, helminths, and protozoa. While the examples provided herein describe specific methods of detecting levels of these markers, the skilled artisan appreciates that the invention is not limited to such methods. Marker levels are quantifiable by any standard method, such methods include, but are not limited to real-time PCR, Southern blot, PCR, and/or mass spectroscopy.
  • the level of any two or more of the markers described herein defines the marker profile of a disease, disorder, or condition.
  • the level of marker is compared to a reference.
  • the reference is the level of marker present in a control sample obtained from a patient that does not have breast cancer.
  • the reference is a healthy tissue or cell (i.e., that is negative for breast cancer).
  • the reference is a baseline level of marker present in a biologic sample derived from a patient prior to, during, or after treatment for ovarian cancer.
  • the reference is a standardized curve.
  • the level of any one or more of the markers described herein is used, alone or in combination with other standard methods, to characterize the disease, disorder, or condition (e.g., breast cancer).
  • one or more organisms described herein may be isolated or extracted from a sample using a capture reagent (e.g., an antibody) and/or detected using ELISA.
  • a capture reagent e.g., an antibody
  • reagents for capturing the pathogenic organism include Streptavidin bound magnetic beads and biotin labeled probes. Such techniques can be further used to obtain nucleic acids pathogenic organism detection using nucleic acid based probes or for direct sequencing (e.g., MiSeq; Illumina).
  • Tumors needing macro-dissection were received in the form of ⁇ sections on glass slides with marked guiding H&E slides, while tumors that did not require macro- dissection were received as ⁇ paraffin rolls.
  • the 20 non-matched control tissues were derived from breast reduction surgeries and obtained as ⁇ paraffin rolls.
  • a resident pathologist reviewed case histories, confirmed the tumor types and demarcated the cancer cells. All the samples were de-identified FFPE (formalin fixed paraffin embedded) samples of breast tumors or controls, and were received from the Abramson Cancer Center Tumor Tissue and Biosample Core.
  • PathoChip design sample preparation and microarray processing:
  • the PathoChip Array design has been previously described in detail (Baldwin et al. MBio. 2014; 5 : e01714-14). Including all the genomes of all known viruses as well as known human bacterial, parasitic and fungal pathogens the probes were generated in silico.
  • the PathoChip comprises 60,000 probe sets manufactured as Sure Print glass slide microarrays
  • FFPE formalin-fixed paraffin- embedded
  • the WTA products were analyzed by agarose gel electrophoresis. Human reference RNA and DNA were also extracted from the human B cell line, BJAB and were used for WTA as previously described (Banerjee et al. Sci Rep. 2015; 5: 15162).
  • the WTA products were purified, (PCR purification kit, Qiagen, Germantown, MD, USA); the WTA products from the cancers were labelled with Cy3 and those from the human reference DNA were labelled with Cy5 (SureTag labeling kit, Agilent Technologies, Santa Clara, CA).
  • the labelled DNAs were purified and hybridized to the PathoChip as described previously (Banerjee et al. Sci Rep. 2015; 5: 15162). Post-hybridization, the slides were washed, scanned and visualized using an Agilent SureScan G4900DA array scanner (Banerjee et al Sci Rep. 2015; 5: 15162).
  • normalized signal was log2 transformed of green signals / scale factors modified red signals (log2 g - log2 scale factor * r).
  • log2 g - log2 scale factor * r modified red signals
  • one-sided t-test was applied to select probes significantly present in cancer samples by comparing cancer samples versus controls.
  • the significance cut-off was log2 fold change of signal > 1 and adjust p value ⁇ 0.01, control prevalence ⁇ 25%, case prevalence > 40%. Prevalence was calculated based on the detection of the signatures in the cancer and the control samples as percentage.
  • the cancer samples were also subjected to hierarchical clustering, based on the detection of microbial signatures in the samples.
  • a hierarchical clustering technique (Euclidean distance, complete linkage, normalized hybridization signals not scaled) was used to cluster the samples. Then clusters were validated by CH index (Calinski and Harabasz index) which is implemented in an R package as NbClust (Charrad et al.
  • CH index is a cluster index that maximizes inter-cluster distances and minimizes intra-cluster distances. Possible cluster solutions were calculated that would maximize the index values to achieve the best clustering of the data. Statistical significance between different groups was determined using the two-sided t-test.
  • PCR primers from the conserved and/or specific regions of the micro-organisms detected by PathoChip screen were used.
  • the PCR amplification reaction mixtures for each reaction contained 200-400 ng of WTA product and 20 pm each of forward and reverse primers (FIG. 13), 300 ⁇ of dNTPs and 2.5U of LongAmp Taq DNA polymerase (NEB).
  • DNA was denatured at 94°C for 3 min, followed by 30 cycles of 94°C for 30 s, different annealing temperatures for different sets of primers for 30-45 s, and 65°C for 30 s.
  • the PCR conditions for each of the primer sets are displayed in FIG. 13.
  • Example 1 Microbial signatures associated with different breast cancer types
  • FIG. 7 Unique and common microbial signatures associated with different breast cancer types have been listed in FIG. 7 and are represented in FIGs. 1A, 2B, 3C and 3F.
  • the average hybridization signal for each probe in the cancer samples was compared to the controls. Those probes that detected significant hybridization signals in the cancer samples (p-value ⁇ 0.05, log fold change in hybridization signal >logl), were considered.
  • the average hybridization signals of the significant probes for each microbial genera and viral families are shown in FIGs. 1A-1E, FIGs. 2A-2E and FIGs 3A-3F.
  • FIGs. 1A-1E The average hybridization signals of the significant probes for each microbial genera and viral families are shown in FIGs. 1A-1E, FIGs. 2A-2E and FIGs 3A-3F.
  • Example 2 Viral signatures associated with different breast cancer types Significant hybridization (described above), at levels above the controls, was detected for 28 viral families among the four breast cancer types (FIGs. 1A and ID). Of these, 17 viral families were detected with significantly higher hybridization signals in greater than 50% of the samples representing all 4 breast cancer types, as compared to the controls (FIGs. IB and ID). They included signatures of Adenoviridae, Anelloviridae,
  • Arenaviridae Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Herpesviridae, Iridoviridae, Papillomaviridae, Paramyxoviridae, Parvoviridae, Picornaviridae,
  • BRTN samples had low or no prevalence of Arteriviridae, Astroviridae, Birnaviridae, Caliciviridae, Circoviridae, Hepadnaviridae, Nodaviridae, Orthomyxoviridae, Polyomaviridae and Togaviridae;
  • BRHR samples show low or no prevalence of Birnaviridae, Hepadnaviridae and Hepeviridae;
  • BRTP samples show low or no prevalence of Caliciviridae and Nodaviridae;
  • BRER samples show low or no prevalence of Arteriviridae, Birnaviridae, Hepeviridae and Nodaviridae.
  • Hybridization signal intensity offered an additional way to compare the data.
  • probes for polyomaviridae were detected with the highest hybridization signal in the BRHRs, followed by BRERs and BRTPs (FIG. IE).
  • probes of Hepadnaviridae were significantly detected with low hybridization signal in the BRTNs (FIG. IE), while detected with higher hybridization signal intensity [log fold change in hybridization signal >1] in the BRERs and BRTPs (FIG. IE).
  • Signatures of Herpesviridae, Adenoviridae, Poxviridae were detected in >90% of the BRER samples screened (FIG. ID), while the highest hybridization signal was detected for Anelloviridae and Flaviviridae (FIG. IB).
  • Signatures of Astroviridae, Herpesviridae, Reoviridae were detected in all of the BRTP samples tested (FIG. ID), with the highest hybridization signal detected for Polyomaviridae signatures (FIG. 1C).
  • signatures of Reoviridae and Flaviviridae were detected in >90% of the samples screened (FIG.
  • Example 3 Bacterial signatures associated with different breast cancer types
  • FIGs. 2A-2E shows the analysis of bacterial signatures in the 4 breast cancer types.
  • Significant hybridization signals common to all 4 breast cancer types were detected for Actinomyces, Bartonella, Brevundimonas, Coxiella, Mobiluncus, Mycobacterium, Rickettsia and Sphingomonas (FIGs. 2B-2C).
  • FIG. 2E shows the marked diversity in bacterial signatures between the breast cancer types. Distinct bacterial signatures uniquely associated with each type of breast cancer analyzed were identified. In this regard BRTN had the least complex bacterial signature, while BRER was the most complex. Signals for Arcanobacterium,
  • Bifidobacterium, Cardiobacterium, Citrobacter, Escherichia were significantly detected in the BRER samples compared to the controls, while those of Bordetella, Campylobacter, Chlamydia, Chlamydophila, Legionella and Pasteurella were significantly associated with the BRTPs.
  • Signals for Streptococcus were detected significantly in the BRHRs, whereas, Aerococcus, Arcobacter, Geobacillus, Orientia and Rothia were found associated with the BRTNs.
  • Hybridization signal intensity again provided an additional view of the complexity of the bacterial microbiome and its diversity among the different breast cancers (FIGs. 2C-2D).
  • Signals for Brevundimonas were detected with higher average hybridization signals in the endocrine receptor positive BRER and BRTP compared to the endocrine receptor negative BRHR and BRTN (FIGs. 2C-2D).
  • Hybridization signals of Mobiluncus and Mycobacterium were predominantly detected in the endocrine receptor negative samples.
  • the bacterial probes detected with the highest hybridization signals were those for Acinetobacter in BRER and BRHR samples, Brevundimonas in BRTP samples and
  • the data showed that the cancer samples had a robust bacterial signature with significant and defining differences between the four breast cancer types.
  • Example 4 Fungal signatures associated with different breast cancer types
  • FIG. 3B-3C show the unique fungal signatures associated with different breast cancer types.
  • FIG. 3D-3E Significant hybridization, above the levels of the controls, was detected for 29 different genera of parasites among the 4 types of breast cancer. As in the case of the fungi, no single genus of parasite was significantly detected in all four breast cancer types (FIGs. 3E-3F). Each cancer showed a relatively distinct parasitic signature pattern, with BRHR showing the least diverse signatures.
  • FIG. 7 and FIG. 3F show the unique and common parasitic signatures among the different breast cancer types.
  • BRER samples, Brugia showed the highest hybridization signal intensity (FIG. 3D), while Thelazia showed the highest prevalence (FIG. 3E).
  • Signatures of Brugia and Paragonimus were only detected in BRER samples. Ancylostoma, Angiostrongylus, Echinococcus, Sarcocystis, Trichomonas, Trichostrongylus were found uniquely associated with BRTP samples. Balamuthia signatures were associated significantly with BRHR samples, and that of Centrocestus, Contracaecum, Leishmania, Necator, Onchocerca, Toxocara, Trichinella, Trichuris were detected significantly only with BRTN samples.
  • Example 6 Hierarchical clustering of the breast cancer samples based on the detection of microbial signatures
  • FIG. 4A-4D Using the hierarchical clustering analysis based on the detection of microbial signatures associated with the 4 breast cancer types it was determined whether the breast cancer types fell into any unique and identifiable clusters. While this analysis identified distinct clusters in each of the breast cancer types based on the detection of their microbial signature patterns (FIGs. 4A-4D), it also defined the distinct microbial signature pattern found in BRTNs and BRTPs whereas, BRER and BRHR shared similar microbial signatures (FIG. 4E). Individually, the different BC types fell into distinct microbial signature clusters. BRER samples fell into 2 distinct clusters 1ER and 2ER, along with 2 ungrouped samples (ungrouped 1ER) (FIG. 4A).
  • the BRHR samples formed 2 major clusters (cluster 1HR and cluster 2HR) (FIG. 4C), and they differed from each other in having higher detection of certain bacterial and viral signatures in cluster 2HR compared to samples in cluster 1HR (FIG. 11).
  • Cluster ITN differed from Cluster 2TN in having higher detection of bacterial probes of Caulobacter
  • the ungrouped samples differed from the grouped samples in having significantly higher detection of certain viral probes of Anelloviridae, Retroviridae, Poxviridae and Arenaviridae compared to Cluster 1TN and Cluster 2TN samples (FIG. 12).
  • FIG. 4E shows the comparison of the microbiome signatures from all four breast cancer types together in the clustering analysis.
  • the data show that the different breast cancers grouped into 4 major clusters plus a few ungrouped BRER (2 samples), BRHR (3 samples) and BRTN (2 samples) samples (ungrouped 1, 2 and 3 respectively).
  • Most of the BRTNs were very distinct in their microbial signature pattern association, and they clustered together (cluster 3).
  • cluster 3 clustered together
  • all the BRTPs screened clustered together to form a distinct cluster 4.
  • most of the BRER samples shared a similar microbial signature pattern with all of the BRHR samples forming the distinct cluster 1, while the remaining 11 BRER samples formed cluster 2.
  • the BRERs in cluster 2 differed from those in Cluster 1 in having significant higher hybridization signals for certain bacterial signatures like Brevundimonas, Sphingomonas, Erysipelothrix, Mycoplasma, Brucella, Prevotella, Arcanobacterium, Staphylococcus, Rickettsia, Propionibacterium,
  • Lactobacillus Shigella, viral signatures of Polyomaviridae, Circoviridae, Herpesviridae, Papillomaviridae, Retroviridae, Orthomyxoviridae, Flaviviridae, Iridoviridae, Poxviridae, Reoviridae, fungal signatures of Trichophyton, Mucor, Rhodotorula, Geotrichum, Pleistophora and parasitic signatures of Paragonimus, Macracanthorhynchus,
  • viruses and microorganisms detected in the BC samples were selected for verification by non-quantitative PCR and sequencing, these included several viral families and individual viruses (Herpesvirus, Polyoma, Papilloma, Parapox and MMTV), as well as a prevalent bacterium (Brevundimonas) and fungus (Pleistophora).
  • the primers used were either previously published (FIG. 13) or were designed based on sequences from the conserved and specific regions of the micro-organisms.
  • pan parasite diagnostic PCR primers were used enabling exhaustive detection of non-human eukaryotic species-specific small subunit rDNA in human clinical samples.
  • the same amplification products used for the screening were used.
  • the amplification products of all the samples for each type of cancer were pooled together and 200-400ng of the products were used for PCR. The same protocol was used for the controls.
  • the PCR amplification showed the expected amplicons for the PathoChip-detected viruses, as well as the selected bacterium, fungus and parasite (FIGs. 5A-5B). Sequencing of the PCR products verified the detection of the appropriate virus or other microorganism (FIG. 14).
  • the human microbiome is comprised of mutualistic, pathogenic, transient and residential viruses and microorganisms. Many recent studies have suggested that the body's microbiome dramatically affects health, where perturbation of the microbiome leads to altered physiology and pathology, including cancer. However, the reverse may also be true, that different human diseases create disease microenvironments amenable to the persistence of a differential microbiome, with or without a direct effect of the establishment or progression of the disease. Such differential microbiomes could be specific to each such disease, thus a biomarker. Using the metagenomic array technology PathoChip, distinct microbiome signatures were previously established in triple negative breast cancers (BRTNs) (Banerjee et al. Sci Rep. 2015; 5 : 15162).
  • BRTNs triple negative breast cancers
  • BRTN major breast cancer types
  • BRTP major breast cancer types
  • BRER BRHR
  • BRTP major breast cancer types
  • BRER BRHR
  • the data showed that the various breast cancers have a robust and varied microbiome with aspects that are unique to each type as well as shared components.
  • the data demonstrate that breast cancer microbiome signatures provide type-specific biomarkers.
  • all four breast cancer types had dominant signatures for Proteobacteria followed by Firmicutes.
  • the signature of the proteobacteria Brevundimonas genus was detected with high hybridization signal and prevalence in all four breast cancer types.
  • the Mobiluncus family was detected in all four types. Actinomyces signatures were also detected in all four breast cancers, especially in BRHRs where it was detected with very high signal intensity. All of the bacterial families detected in all four breast cancers could serve as a biomarker for breast cancer in general. However, each type of breast cancer held signatures for unique bacterial genera, which provides the ability to detect specific breast cancer types.
  • Rhodotorula Trichosporon as well as fungi causing Mucormycosis, Aspergillosis (cutaneous infections) and dermatophytes like Epidermophyton and Trichophyton. Also,

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions et des procédés pour la détection du cancer du sein. L'invention comprend en outre la détection et la distinction des différents types de cancer du sein (BRTN, BRTP, BRER et BRHR). L'invention concerne également des compositions et des procédés pour détecter une signature métagénomique dans un échantillon de tissu prélevé chez un sujet qui indique que le sujet est atteint d'un cancer du sein et/ou d'un type spécifique de cancer du sein.
PCT/US2018/029572 2017-04-26 2018-04-26 Compositions et procédés de détection de signatures microbiennes associées à différents types de cancer du sein WO2018200813A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762490375P 2017-04-26 2017-04-26
US62/490,375 2017-04-26

Publications (1)

Publication Number Publication Date
WO2018200813A1 true WO2018200813A1 (fr) 2018-11-01

Family

ID=63920033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/029572 WO2018200813A1 (fr) 2017-04-26 2018-04-26 Compositions et procédés de détection de signatures microbiennes associées à différents types de cancer du sein

Country Status (1)

Country Link
WO (1) WO2018200813A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020093040A1 (fr) * 2018-11-02 2020-05-07 The Regents Of The University Of California Procédés de diagnostic et de traitement du cancer à l'aide d'acides nucléiques non humains
WO2021242819A1 (fr) * 2020-05-29 2021-12-02 The Trustees Of The University Of Pennsylvania Compositions et procédés de détection de virus respiratoires comprenant des coronavirus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070134652A1 (en) * 2005-11-09 2007-06-14 Primera Biosystems, Inc. Multiplexed quantitative detection of pathogens
WO2016172179A2 (fr) * 2015-04-20 2016-10-27 The Trustees Of The University Of Pennsylvania Compositions métagénomiques et méthodes pour la détection du cancer du sein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070134652A1 (en) * 2005-11-09 2007-06-14 Primera Biosystems, Inc. Multiplexed quantitative detection of pathogens
WO2016172179A2 (fr) * 2015-04-20 2016-10-27 The Trustees Of The University Of Pennsylvania Compositions métagénomiques et méthodes pour la détection du cancer du sein

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020093040A1 (fr) * 2018-11-02 2020-05-07 The Regents Of The University Of California Procédés de diagnostic et de traitement du cancer à l'aide d'acides nucléiques non humains
CN112930407A (zh) * 2018-11-02 2021-06-08 加利福尼亚大学董事会 使用非人类核酸诊断和治疗癌症的方法
EP3874068A4 (fr) * 2018-11-02 2022-08-17 The Regents of the University of California Procédés de diagnostic et de traitement du cancer à l'aide d'acides nucléiques non humains
WO2021242819A1 (fr) * 2020-05-29 2021-12-02 The Trustees Of The University Of Pennsylvania Compositions et procédés de détection de virus respiratoires comprenant des coronavirus
CN116209776A (zh) * 2020-05-29 2023-06-02 宾夕法尼亚大学董事会 用于检测包括冠状病毒在内的呼吸道病毒的组合物和方法

Similar Documents

Publication Publication Date Title
CN104017908B (zh) 人乳头状瘤病毒的快速基因型鉴定分析及其装置
EP2007901B1 (fr) Analyse rapide de genotypage et dispositif associe
WO2005038039A2 (fr) Procede et kit pour l'amplification multiplex par amorces d'acides nucleiques
CN101906486B (zh) 检测多种鱼类病原的基因芯片及其检测方法
US20180291457A1 (en) Metagenomic compositions and methods for the detection of breast cancer
WO2014114189A1 (fr) Procédés et compositions pour détecter un snp cible
US9057103B2 (en) Method for detecting mutations at IL28B and ITPA
US20210363598A1 (en) Compositions and methods for metagenome biomarker detection
JP4909413B2 (ja) 一般化された方法―特異的な配列補完（ｄｓｆ）により可能になる連続的アダプター連結および増幅を用いたハイスループット突然変異スクリーニング法およびキット
WO2018200813A1 (fr) Compositions et procédés de détection de signatures microbiennes associées à différents types de cancer du sein
CN113930500A (zh) 人pik3ca基因突变的数字pcr检测方法及应用
EP1426448A1 (fr) Procédé pour réduire les effects des variations de séquence dans un procédé d'hybridisation diagnostique, sonde de l'usage dans un tel procédé, et procédé
EP2839025B1 (fr) Compositions et procédés de détection de micro-organismes du complexe mycobacterium avium à l'exception de mycobacterium avium paratuberculosis
US20180291463A1 (en) Compositions and Methods for Detecting the Ovarian Cancer Oncobiome
WO2018031545A1 (fr) Compositions et méthodes de détection de carcinomes à cellules squameuses de la cavité buccale
WO2022020259A1 (fr) Méthodes et dispositifs pour détecter et séquencer le sars-cov-2
CN117165665A (zh) 一种多基因甲基化检测方法及其应用
JP2008161170A (ja) 高感度なサルモネラ属菌検出用オリゴヌクレオチド、それを用いた検出方法および検出キット
CN113930501A (zh) 人egfr基因突变的数字pcr检测方法及应用
CN113897429A (zh) 人nras基因突变的数字pcr检测方法及应用
CN112342304B (zh) 水牛21个str位点的荧光标记复合扩增试剂盒及其应用
EP4157534A1 (fr) Compositions et procédés de détection de virus respiratoires comprenant des coronavirus
US20240218375A1 (en) Dna aptamer specifically binding to methylated dna fragment and selection method and use thereof
JP2013094116A (ja) Ｓｌｃ２８ａ１／ａ２／ａ３遺伝子の多型検出用プローブおよびその用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18791766

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18791766

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载